Notably, combined treatment with a MEK inhibitor (Trametinib, which is approved by the Food and Drug Administration, FDA, for clinical use) and an AMPK inhibitor (Compound C) triggers a synergistic cytotoxic effect and potentiates the antitumor activity of each single agent in metabolically stressed cancer cells [47]. This evidence concerns the gene MAP2K7 and cancer.